TY - JOUR
T1 - Survival benefit of boron neutron capture therapy for recurrent malignant gliomas
AU - Miyatake, Shin Ichi
AU - Kawabata, Shinji
AU - Yokoyama, Kunio
AU - Kuroiwa, Toshihiko
AU - Michiue, Hiroyuki
AU - Sakurai, Yoshinori
AU - Kumada, Hiroaki
AU - Suzuki, Minoru
AU - Maruhashi, Akira
AU - Kirihata, Mitsunori
AU - Onoc, Koji
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/7
Y1 - 2009/7
N2 - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.
AB - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.
KW - Boronophenylalanine PET
KW - Glioblastoma
KW - Malignant glioma
KW - Recursive partitioning analysis (RPA)
UR - http://www.scopus.com/inward/record.url?scp=67649389423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649389423&partnerID=8YFLogxK
U2 - 10.1016/j.apradiso.2009.03.032
DO - 10.1016/j.apradiso.2009.03.032
M3 - Article
C2 - 19394240
AN - SCOPUS:67649389423
VL - 67
SP - S22-S24
JO - Applied Radiation and Isotopes
JF - Applied Radiation and Isotopes
SN - 0969-8043
IS - 7-8 SUPPL.
ER -